Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells
-
Published:2023-04-03
Issue:4
Volume:5
Page:642-659
-
ISSN:2522-5812
-
Container-title:Nature Metabolism
-
language:en
-
Short-container-title:Nat Metab
Author:
Green Alanna C.ORCID, Marttila PetraORCID, Kiweler NicoleORCID, Chalkiadaki Christina, Wiita Elisée, Cookson Victoria, Lesur Antoine, Eiden Kim, Bernardin FrançoisORCID, Vallin Karl S. A., Borhade Sanjay, Long Maeve, Ghahe Elahe Kamali, Jiménez-Alonso Julio J., Jemth Ann-SofieORCID, Loseva Olga, Mortusewicz OliverORCID, Meyers Marianne, Viry Elodie, Johansson Annika I.ORCID, Hodek OndřejORCID, Homan Evert, Bonagas NadillyORCID, Ramos LouiseORCID, Sandberg Lars, Frödin Morten, Moussay EtienneORCID, Slipicevic Ana, Letellier ElisabethORCID, Paggetti JérômeORCID, Sørensen Claus Storgaard, Helleday ThomasORCID, Henriksson MartinORCID, Meiser JohannesORCID
Abstract
AbstractCancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase–cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2, and selectively kills cancer cells. Here, we reveal that, in cells, TH9619 targets nuclear MTHFD2 but does not inhibit mitochondrial MTHFD2. Hence, overflow of formate from mitochondria continues in the presence of TH9619. TH9619 inhibits the activity of MTHFD1 occurring downstream of mitochondrial formate release, leading to the accumulation of 10-formyl-tetrahydrofolate, which we term a ‘folate trap’. This results in thymidylate depletion and death of MTHFD2-expressing cancer cells. This previously uncharacterized folate trapping mechanism is exacerbated by physiological hypoxanthine levels that block the de novo purine synthesis pathway, and additionally prevent 10-formyl-tetrahydrofolate consumption for purine synthesis. The folate trapping mechanism described here for TH9619 differs from other MTHFD1/2 inhibitors and antifolates. Thus, our findings uncover an approach to attack cancer and reveal a regulatory mechanism in 1C metabolism.
Funder
Weston Park Cancer Centre and the University of Sheffield Helleday Foundation Deutsche Forschungsgemeinschaft Fonds National de la Recherche Luxembourg Ministerio de Universidades of the Spanish Government Karolinska Institute’s KID funding for doctoral students One-Carbon Therapeutics AB Novo Nordisk Fonden Cancerfonden Barncancerfonden Vetenskapsrådet VINNOVA Weston Park Cancer Centre and the University of Sheffield Torsten and Ragnar Söderberg Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Physiology (medical),Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference43 articles.
1. Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435–446 (2011). 2. Helleday, T. & Rudd, S. G. Targeting the DNA damage response and repair in cancer through nucleotide metabolism. Mol. Oncol. 16, 3792–3810 (2022). 3. Henriksson, S., Groth, P., Gustafsson, N. & Helleday, T. Distinct mechanistic responses to replication fork stalling induced by either nucleotide or protein deprivation. Cell Cycle 17, 568–579 (2018). 4. Locasale, J. W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13, 572–583 (2013). 5. Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16, 650–662 (2016).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|